XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Segments (Tables)
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Operations and Assets for Operating Segments and Geographic Information
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 For the three months ended September 30,For the nine months ended September 30,
(In thousands)2021202020212020
Revenue from services:
Pharmaceutical$— $— $— $— 
Diagnostics340,163 382,498 1,244,312 804,309 
Corporate— — — — 
$340,163 $382,498 $1,244,312 $804,309 
Revenue from products:
Pharmaceutical$36,882 $28,702 $106,490 $89,133 
Diagnostics— — — — 
Corporate— — — — 
$36,882 $28,702 $106,490 $89,133 
Revenue from transfer of intellectual property and other:
Pharmaceutical$8,768 $6,819 $22,585 $31,057 
Diagnostics— 10,045 — 16,240 
Corporate— — — — 
$8,768 $16,864 $22,585 $47,297 
Operating income (loss):
Pharmaceutical$28,617 $(14,425)$(4,251)$(34,546)
Diagnostics19,656 46,172 116,670 68,975 
Corporate(10,447)(9,808)(30,585)(26,071)
$37,826 $21,939 $81,834 $8,358 
Depreciation and amortization:
Pharmaceutical$6,080 $7,316 $20,500 $21,556 
Diagnostics12,883 13,720 39,025 43,739 
Corporate— — — — 
$18,963 $21,036 $59,525 $65,295 
Loss from investment in investees:
Pharmaceutical$(53)$(110)$(163)$(433)
Diagnostics— — — — 
Corporate— — — — 
$(53)$(110)$(163)$(433)
Revenues:
United States$354,586 $400,778 $1,269,749 $847,539 
Ireland5,445 8,988 24,663 37,736 
Chile16,486 11,062 49,294 33,064 
Spain5,721 3,713 17,077 12,005 
Israel307 1,119 3,543 4,010 
Mexico3,162 2,280 8,619 5,987 
Other106 124 442 398 
$385,813 $428,064 $1,373,387 $940,739 
(In thousands)September 30,
2021		December 31,
2020
Assets:
Pharmaceutical$1,109,600 $1,176,245 
Diagnostics1,234,477 1,268,738 
Corporate73,561 28,080 
$2,417,638 $2,473,063 
Goodwill:
Pharmaceutical$239,765 $245,793 
Diagnostics434,809 434,809 
Corporate— — 
$674,574 $680,602